Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Schizophrenia

Free Subscription Articles published in Neuropsychopharmacology Retrieve available abstracts of 41 articles: HTML format Text format

Single Articles

March 2010
1. FARRELL M , Roth BL
   Allosteric antipsychotics: m4 muscarinic potentiators as novel treatments for schizophrenia.
   Neuropsychopharmacology. 2010;35:851-2.
   PubMed     Text format     Related articles   
   
   
   February 2010
2. MCCLURE MM , Harvey PD, Goodman M, Triebwasser J, et al
   Pergolide Treatment of Cognitive Deficits Associated with Schizotypal Personality Disorder: Continued Evidence of the Importance of the Dopamine System in the Schizophrenia Spectrum.
   Neuropsychopharmacology. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   January 2010
3. TIWARI AK , Zai CC, Likhodi O, Lisker A, et al
   A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia.
   Neuropsychopharmacology. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
4. GOLDBERG TE , Keefe RS, Goldman RS, Robinson DG, et al
   Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies.
   Neuropsychopharmacology. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
5. BARAKAUSKAS VE , Beasley CL, Barr AM, Ypsilanti AR, et al
   A Novel Mechanism and Treatment Target for Presynaptic Abnormalities in Specific Striatal Regions in Schizophrenia.
   Neuropsychopharmacology. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
6. NICULESCU AB , Le-Niculescu H
   Convergent Functional Genomics: what we have learned and can learn about genes, pathways, and mechanisms.
   Neuropsychopharmacology. 2010;35:355-6.
   PubMed     Text format     Related articles   
   
   
   
7. BORGLAND SL , Labouebe G
   Orexin/hypocretin in psychiatric disorders: present state of knowledge and future potential.
   Neuropsychopharmacology. 2010;35:353-4.
   PubMed     Text format     Related articles   
   
   
   
8. MARGOLIS RL , Ross CA
   Neuronal signaling pathways: genetic insights into the pathophysiology of major mental illness.
   Neuropsychopharmacology. 2010;35:350-1.
   PubMed     Text format     Related articles   
   
   
   
9. MIZRAHI R
   Advances in PET analyses of stress and dopamine.
   Neuropsychopharmacology. 2010;35:348-9.
   PubMed     Text format     Related articles   
   
   
   December 2009
10. SAMBATARO F , Blasi G, Fazio L, Caforio G, et al
    Treatment with Olanzapine is Associated with Modulation of the Default Mode Network in Patients with Schizophrenia.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. TREGELLAS JR , Olincy A, Johnson L, Tanabe J, et al
    Functional Magnetic Resonance Imaging of Effects of a Nicotinic Agonist in Schizophrenia.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2009
12. MELTZER HY , Mills R, Revell S, Williams H, et al
    Pimavanserin, a Serotonin(2A) Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. KINON BJ , Chen L, Ascher-Svanum H, Stauffer VL, et al
    Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2009
14. DONOHOE G , Frodl T, Morris D, Spoletini I, et al
    Reduced Occipital and Prefrontal Brain Volumes in Dysbindin-Associated Schizophrenia.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. RAPAPORT MH , Bresee C
    Serial Mitogen-Stimulated Cytokine Production from Continuously Ill Patients with Schizophrenia.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. BENES FM
    Amygdalocortical Circuitry in Schizophrenia: From Circuits to Molecules.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
17. EISENBERG DP , Berman KF
    Executive Function, Neural Circuitry, and Genetic Mechanisms in Schizophrenia.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. ALEXANDER KS , Brooks JM, Sarter M, Bruno JP, et al
    Disruption of Mesolimbic Regulation of Prefrontal Cholinergic Transmission in an Animal Model of Schizophrenia and Normalization by Chronic Clozapine Treatment.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
19. LAHTI AC , Weiler MA, Holcomb HH, Tamminga CA, et al
    Modulation of Limbic Circuitry Predicts Treatment Response to Antipsychotic Medication: A Functional Imaging Study in Schizophrenia.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2009
20. FEIFEL D , Mexal S, Melendez G, Liu PY, et al
    The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog.
    Neuropsychopharmacology. 2009;34:2011-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
21. WANG HX , Gao WJ
    Cell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex.
    Neuropsychopharmacology. 2009;34:2028-40.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2009
22. GAISLER-SALOMON I , Miller GM, Chuhma N, Lee S, et al
    Glutaminase-Deficient Mice Display Hippocampal Hypoactivity, Insensitivity To Pro-Psychotic Drugs And Potentiated Latent Inhibition: Relevance To Schizophrenia.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2009
23. SALAH-UDDIN H , Scarr E, Pavey G, Harris K, et al
    Altered M(1) Muscarinic Acetylcholine Receptor (CHRM1)-Galpha(q/11) Coupling in a Schizophrenia Endophenotype.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
24. MARX CE , Keefe RS, Buchanan RW, Hamer RM, et al
    Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2009
25. CRUZ DA , Weaver CL, Lovallo EM, Melchitzky DS, et al
    Selective Alterations in Postsynaptic Markers of Chandelier Cell Inputs to Cortical Pyramidal Neurons in Subjects with Schizophrenia.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2009
26. KONRAD A , Vucurevic G, Musso F, Stoeter P, et al
    ErbB4 genotype predicts left frontotemporal structural connectivity in human brain.
    Neuropsychopharmacology. 2009;34:641-50.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2009
27. BARAK S , Arad M, De Levie A, Black MD, et al
    Pro-Cognitive and Antipsychotic Efficacy of the alpha7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. GUO X , Hamilton PJ, Reish NJ, Sweatt JD, et al
    Reduced Expression of the NMDA Receptor-Interacting Protein SynGAP Causes Behavioral Abnormalities that Model Symptoms of Schizophrenia.
    Neuropsychopharmacology. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
29. CONN PJ , Jones CK
    Promise of mGluR2/3 activators in psychiatry.
    Neuropsychopharmacology. 2009;34:248-9.
    PubMed     Text format     Related articles   
    
    
    December 2008
30. KARLSSON RM , Tanaka K, Saksida LM, Bussey TJ, et al
    Assessment of Glutamate Transporter GLAST (EAAT1)-Deficient Mice for Phenotypes Relevant to the Negative and Executive/Cognitive Symptoms of Schizophrenia.
    Neuropsychopharmacology. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. CASEY DE , Daniel DG, Tamminga C, Kane JM, et al
    Divalproex ER Combined with Olanzapine or Risperidone for Treatment of Acute Exacerbations of Schizophrenia.
    Neuropsychopharmacology. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
32. WALTZ JA , Schweitzer JB, Gold JM, Kurup PK, et al
    Patients with Schizophrenia have a Reduced Neural Response to Both Unpredictable and Predictable Primary Reinforcers.
    Neuropsychopharmacology. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
33. ROWLAND LM , Spieker EA, Francis A, Barker PB, et al
    White Matter Alterations in Deficit Schizophrenia.
    Neuropsychopharmacology. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
34. IZUMI A , Iijima Y, Noguchi H, Numakawa T, et al
    Genetic variations of human neuropsin gene and psychiatric disorders: polymorphism screening and possible association with bipolar disorder and cognitive functions.
    Neuropsychopharmacology. 2008;33:3237-45.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2008
35. LIEBERMAN JA , Papadakis K, Csernansky J, Litman R, et al
    A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia.
    Neuropsychopharmacology. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
36. GRAFF-GUERRERO A , Mizrahi R, Agid O, Marcon H, et al
    The Dopamine D(2) Receptors in High-Affinity State and D(3) Receptors in Schizophrenia: A Clinical [(11)C]-(+)-PHNO PET Study.
    Neuropsychopharmacology. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2008
37. WANG PS , Heinssen R, Oliveri M, Wagner A, et al
    Bridging Bench and Practice: Translational Research for Schizophrenia and Other Psychotic Disorders.
    Neuropsychopharmacology. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2008
38. WANG CZ , Yang SF, Xia Y, Johnson KM, et al
    Postnatal phencyclidine administration selectively reduces adult cortical parvalbumin-containing interneurons.
    Neuropsychopharmacology. 2008;33:2442-55.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2008
39. TURETSKY BI , Hahn CG, Arnold SE, Moberg PJ, et al
    Olfactory Receptor Neuron Dysfunction in Schizophrenia.
    Neuropsychopharmacology. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
40. ABLER B , Greenhouse I, Ongur D, Walter H, et al
    Abnormal reward system activation in mania.
    Neuropsychopharmacology. 2008;33:2217-27.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2008
41. BAKER DA , Madayag A, Kristiansen LV, Meador-Woodruff JH, et al
    Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine.
    Neuropsychopharmacology. 2008;33:1760-72.
    PubMed     Text format     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: